BRPI0913468A2 - polímero anfifílico quelante que tem a capacidade de auto-montagem, partícula, uso de uma partícula, agente de contranste de cest mri, agente de contraste de spect ou pet, agente de contraste de ct espectral, e método de produção de uma particula - Google Patents

polímero anfifílico quelante que tem a capacidade de auto-montagem, partícula, uso de uma partícula, agente de contranste de cest mri, agente de contraste de spect ou pet, agente de contraste de ct espectral, e método de produção de uma particula

Info

Publication number
BRPI0913468A2
BRPI0913468A2 BRPI0913468A BRPI0913468A BRPI0913468A2 BR PI0913468 A2 BRPI0913468 A2 BR PI0913468A2 BR PI0913468 A BRPI0913468 A BR PI0913468A BR PI0913468 A BRPI0913468 A BR PI0913468A BR PI0913468 A2 BRPI0913468 A2 BR PI0913468A2
Authority
BR
Brazil
Prior art keywords
particle
contrast agent
counterstain
spect
spectral
Prior art date
Application number
BRPI0913468A
Other languages
English (en)
Portuguese (pt)
Inventor
Anke De Vries
Erica M G AUSSEMSCUSTERS
Holger Gruell
Johan Lub
Sander Langereis
Original Assignee
Konink Philips Elecronics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Konink Philips Elecronics N V filed Critical Konink Philips Elecronics N V
Publication of BRPI0913468A2 publication Critical patent/BRPI0913468A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
    • C08G81/025—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A61K51/1237—Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
BRPI0913468A 2008-09-09 2009-09-08 polímero anfifílico quelante que tem a capacidade de auto-montagem, partícula, uso de uma partícula, agente de contranste de cest mri, agente de contraste de spect ou pet, agente de contraste de ct espectral, e método de produção de uma particula BRPI0913468A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08163933A EP2161020A1 (fr) 2008-09-09 2008-09-09 Polymères amphiphiliques chélatants
PCT/IB2009/053921 WO2010029500A1 (fr) 2008-09-09 2009-09-08 Polymères chélateurs amphiphiles

Publications (1)

Publication Number Publication Date
BRPI0913468A2 true BRPI0913468A2 (pt) 2015-12-22

Family

ID=40266336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913468A BRPI0913468A2 (pt) 2008-09-09 2009-09-08 polímero anfifílico quelante que tem a capacidade de auto-montagem, partícula, uso de uma partícula, agente de contranste de cest mri, agente de contraste de spect ou pet, agente de contraste de ct espectral, e método de produção de uma particula

Country Status (7)

Country Link
US (2) US9034298B2 (fr)
EP (2) EP2161020A1 (fr)
JP (1) JP5802555B2 (fr)
CN (1) CN102149371B (fr)
BR (1) BRPI0913468A2 (fr)
RU (1) RU2519713C2 (fr)
WO (1) WO2010029500A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109363A2 (fr) 2011-02-08 2012-08-16 The Johns Hopkins University Vecteurs géniques pénétrant le mucus
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
CN102604065B (zh) * 2012-03-27 2013-09-04 中国科学院长春应用化学研究所 交联的生物可降解载体聚合物、胶束、囊泡及其制备方法和应用
US20150133768A1 (en) * 2012-04-17 2015-05-14 The Johns Hopkins University Use of non-metallic cest agents for mri monitoring of nanoparticle delivery
AU2013309496A1 (en) * 2012-08-28 2014-06-05 Original BioMedicals Co., Ltd The controlled release method for a pharmaceutical composition composed of chelating complex micelles
GB2525517B (en) 2012-12-07 2019-12-04 Sambria Pharmaceuticals Llc Topical preparation for pain relief
US10265283B2 (en) 2012-12-07 2019-04-23 Sambria Pharmaceuticals, Llc Topical composition and delivery system and its use
WO2014124006A1 (fr) * 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticules pour le suivi de l'imagerie par résonance magnétique et procédés de fabrication et d'utilisation associés
EA037605B1 (ru) * 2014-02-18 2021-04-20 Медзис Фарма Применение обратно-мицеллярных систем для доставки реагентов, хелатирующих радионуклиды и металлы
WO2015175545A1 (fr) 2014-05-12 2015-11-19 The Johns Hopkins University Plate-formes de vecteurs de gènes biodégradables très stables pour surmonter des barrières biologiques
CN104485193B (zh) * 2014-12-29 2016-11-02 广西师范大学 一种以酰腙类希夫碱为配体构筑的磁性材料及其制备方法
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
GB2555391B (en) * 2016-10-21 2019-06-26 Algipharma As Bacitracin-alginate oligomer conjugates
CN108264016A (zh) * 2017-12-26 2018-07-10 中国科学院合肥物质科学研究院 一种多样性纳米结构复合阵列及其制备方法
CN110496231B (zh) * 2018-05-16 2020-09-18 浙江大学 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用
WO2019241192A1 (fr) * 2018-06-13 2019-12-19 Abbott Diabetes Care Inc. Matériaux de membrane insensibles à la température et capteurs d'analyte les contenant
US20200215198A1 (en) * 2019-01-03 2020-07-09 Ionpath, Inc. Compositions and reagents for ion beam imaging
CN111393547B (zh) * 2020-03-31 2021-10-08 浙江康特生物科技有限公司 一种螯合树脂的制备及去除试剂盒纯化水中锌离子的应用
WO2023240135A2 (fr) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Chélateurs et conjugués bifonctionnels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817292A (en) * 1992-10-14 1998-10-06 Nycomed Imaging As MR imaging compositions and methods
JPH08502528A (ja) * 1992-10-14 1996-03-19 スターリング ウィンスロップ アイエヌシー． キレート化ポリマー
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7045283B2 (en) * 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
KR100448170B1 (ko) 2001-06-23 2004-09-10 주식회사 태평양 폴리에틸렌이민을 친수성 블록으로 갖고 폴리에스테르계고분자를 소수성 블록으로 갖는 양친성 생분해성 블록공중합체 및 이를 이용한 수용액 상에서의 고분자자기조합 회합체
GB0118995D0 (en) * 2001-08-03 2001-09-26 Univ Wales Medicine Detection of mutations in nucleic acids
US7682603B2 (en) 2003-07-25 2010-03-23 The Trustees Of The University Of Pennsylvania Polymersomes incorporating highly emissive probes
US20050180922A1 (en) 2004-02-12 2005-08-18 Discher Dennis E. Block co-polymer worm micelles and methods of use therefor
US8697031B2 (en) * 2004-06-04 2014-04-15 Case Western Reserve University Dual function polymer micelles
JP4758346B2 (ja) * 2004-07-05 2011-08-24 財団法人神奈川科学技術アカデミー 高分子ミセル型ｍｒｉ造影剤
AU2006294486B2 (en) 2005-09-28 2012-11-29 The Trustees Of The University Of Pennsylvania Self-assembled biodegradable polymersomes
US8124128B2 (en) 2005-11-08 2012-02-28 Industrial Technology Research Institute Amphiphilic block copolymers and nano particles comprising the same
WO2007141761A1 (fr) 2006-06-08 2007-12-13 Millard, Paul, Stefanus Embrayage
US8463358B2 (en) * 2006-06-09 2013-06-11 Koninklijke Philips Electronics N.V. Elimination of contrast agent concentration dependency in MRI
FR2908414B1 (fr) 2006-11-13 2012-01-20 Centre Nat Rech Scient Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
JP4892378B2 (ja) * 2007-03-10 2012-03-07 財団法人神奈川科学技術アカデミー 高分子ミセル型ｍｒｉ造影剤
US8303937B2 (en) * 2007-12-31 2012-11-06 Industrial Technology Research Institute Dendritic polymers and magnetic resonance imaging contrast agent employing the same

Also Published As

Publication number Publication date
CN102149371A (zh) 2011-08-10
US20150247008A1 (en) 2015-09-03
CN102149371B (zh) 2017-04-19
RU2519713C2 (ru) 2014-06-20
EP2323636B1 (fr) 2015-08-12
JP5802555B2 (ja) 2015-10-28
EP2323636A1 (fr) 2011-05-25
JP2013503814A (ja) 2013-02-04
WO2010029500A1 (fr) 2010-03-18
RU2011113841A (ru) 2012-10-20
EP2161020A1 (fr) 2010-03-10
US9034298B2 (en) 2015-05-19
US9718929B2 (en) 2017-08-01
US20110165074A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
BRPI0913468A2 (pt) polímero anfifílico quelante que tem a capacidade de auto-montagem, partícula, uso de uma partícula, agente de contranste de cest mri, agente de contraste de spect ou pet, agente de contraste de ct espectral, e método de produção de uma particula
BRPI0809656A2 (pt) Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica
BRPI0917680A2 (pt) multifilamento extrafino contendo um agente de função desodorizante, e, método para produzir um multifilamento extrafino contendo um agente de função desodorizante
BRPI0920030A2 (pt) agente de oclusão do tecido
BRPI0814811A2 (pt) Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem
BRPI0810396A2 (pt) Nanopartícula que compreende um polímero biodegradável, uma ciclodextrina ou um derivado desta, composição farmacêutica e processo para produzir nanopartículas
EP2303288A4 (fr) Conjugués d'un polymère, d'un bisphosphonate et d'un agent anti-angiogenèse et leurs utilisations dans le traitement et la surveillance de maladies concernant les os
EP2344041A4 (fr) Procédé et dispositif pour une imagerie tomographique à rayons x informatisée
BRPI1006733A2 (pt) kit para formação de imagem médica marcada e/ou produtos terapêuticos, agente de pré-marcação, sonda de formação de imagem, sonda terapêutica e método
EP2261261A4 (fr) Fines particules de dérivé de cellulose, dispersions fluides et dispersions solides de celles-ci et médicaments de diagnostic
BRPI0910963A2 (pt) composição imunogênica, método para tratar ou prevenir doença pneumocócica, e , uso de uma composição imunogênica
BRPI0907260A2 (pt) "métodos, dispositivos e composições que liberam óxido nítrico"
BRPI0920272A2 (pt) composição de filtro-solar, método para melhorar a resistência à água de uma composição de filtro-solar, método para melhorar a eficácia de filtro-solar, e, formulação de filtro-solar
BRPI0817290A2 (pt) Métodos, dispositivos, sistemas, conjuntos, e kits para retração de tecido dentro de uma cavidade oral
BRPI0905733A2 (pt) "composição, formulação farmacêutica, método para tratamento de câncer positivo para her2 e método pára a produção de uma composição farmacêutica"
BRPI0909800A2 (pt) uma composição de partícula de pigmento, seu método de fabricação e seu uso
CL2014001059A1 (es) Cuerpo laminar para hacer tejados de invernadero que comprende al menos una capa laminar y una matriz de polimero y nanoparticulas de dioxido de titanio disperso en la matriz de polimero; metodo de cultivo; uso de dicho cuerpo; invernadero; y una mezcla maestra.
HK1145942A1 (en) Systems and methods for ex-vivo organ care using lactate as an indication
EP2308932A4 (fr) Procédé de production d'un polymère colorant, polymère colorant et son utilisation
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
FI20060383A0 (fi) Lääketieteellinen röntgenkuvauslaitteisto ja röntgenilmaisin sen käyttämiseksi
EP2299904A4 (fr) Dispositifs et procédés de diagnostic médical
ATE541846T1 (de) Glucocorticoidmimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und anwendungen davon
FI20106130A (fi) Lääketieteellinen röntgentietokonetomografiakuvantamislaitteisto
IL209894A (en) Compounds for the prevention and / or treatment of β-amyloidosis including Alzheimer's disease

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: KONINKLIJKE PHILIPS N.V. (NL)

B25G Requested change of headquarter approved

Owner name: KONINKLIJKE PHILIPS N.V. (NL)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Ipc: C08G 81/02 (2006.01), A61K 9/107 (2006.01), A61K 9

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2530 DE 02-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.